BR112013006400A2 - - Google Patents
Info
- Publication number
- BR112013006400A2 BR112013006400A2 BR112013006400A BR112013006400A BR112013006400A2 BR 112013006400 A2 BR112013006400 A2 BR 112013006400A2 BR 112013006400 A BR112013006400 A BR 112013006400A BR 112013006400 A BR112013006400 A BR 112013006400A BR 112013006400 A2 BR112013006400 A2 BR 112013006400A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38401510P | 2010-09-17 | 2010-09-17 | |
US61/384,015 | 2010-09-17 | ||
PCT/PT2011/000031 WO2012036580A2 (en) | 2010-09-17 | 2011-09-19 | Antibacterial phage, phage peptides and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013006400A2 true BR112013006400A2 (US07935481-20110503-C00024.png) | 2021-12-07 |
BR112013006400B1 BR112013006400B1 (pt) | 2023-03-21 |
Family
ID=45755483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013006400-5A BR112013006400B1 (pt) | 2010-09-17 | 2011-09-19 | Composição farmacêutica e seu uso, métodos relacionados a uma infecção bacteriana |
Country Status (13)
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3789031B1 (en) * | 2010-09-17 | 2023-08-02 | Technophage, Investigação e Desenvolvimento em Biotecnologia, SA | Antibacterial phage, phage peptides and methods of use thereof |
CN104519893B (zh) | 2012-03-19 | 2020-02-07 | 药物技术业制药技术股份有限公司 | 用于治疗细菌感染的包含抗细菌噬菌体的混合物的组合物及其使用方法 |
EP2847323B1 (en) * | 2012-05-07 | 2018-05-30 | Micreos B.V. | A bacteriophage for biocontrol of salmonella and in the manufacturing or processing of foods |
EP2799063A1 (en) * | 2013-04-30 | 2014-11-05 | Ferring B.V. | Bacteriophage therapy |
EP2865383A1 (en) * | 2013-10-25 | 2015-04-29 | Pherecydes Pharma | Phage therapy of pseudomonas infections |
EP2893933A1 (en) * | 2014-01-10 | 2015-07-15 | Pherecydes Pharma | Phage Therapy of E coli infections |
CN103981154B (zh) * | 2014-05-28 | 2016-07-06 | 大连理工大学 | 一种铜绿假单胞菌噬菌体及其在水貂出血性肺炎预防中的应用 |
NZ728429A (en) * | 2014-06-26 | 2024-07-05 | Univ Rockefeller | Acinetobacter lysins |
EP3018201A1 (en) * | 2014-11-07 | 2016-05-11 | Pherecydes Pharma | Phage therapy |
EA038595B1 (ru) | 2014-12-16 | 2021-09-21 | Си3Джей ТЕРАПЬЮТИКС, ИНК. | Композиции и способы для конструирования вирусного генома in vitro |
EP4115897A1 (en) * | 2015-09-17 | 2023-01-11 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
CN108779445A (zh) * | 2016-03-28 | 2018-11-09 | 亿明达股份有限公司 | 重组酶突变 |
WO2018106135A2 (en) | 2016-12-05 | 2018-06-14 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof |
WO2018151417A1 (ko) * | 2017-02-17 | 2018-08-23 | 주식회사 인트론바이오테크놀로지 | 신규한 녹농균 박테리오파지 Pse-AEP-4 및 이의 녹농균 증식 억제 용도 |
GB201712145D0 (en) * | 2017-07-28 | 2017-09-13 | Univ Leuven Kath | Novel dnase |
KR20210014673A (ko) | 2018-05-30 | 2021-02-09 | 뤼산도 아게 | 신규 항균성 단백질 |
WO2020130652A2 (ko) * | 2018-12-18 | 2020-06-25 | 연세대학교 산학협력단 | 세균을 용균하는 신규한 박테리오파지 |
US20220073567A1 (en) * | 2018-12-24 | 2022-03-10 | Mikroliz Biyoteknoloji San. Ve Tic. Ltd. Sti. | Acinetobacter baumannii bacteriophage mikab48 or lytic protein derived from the bacteriophage |
RU2717973C1 (ru) * | 2019-06-28 | 2020-03-27 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 322 (500316), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
RU2717972C1 (ru) * | 2019-06-28 | 2020-03-27 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 324 (500318), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
RU2717026C1 (ru) * | 2019-06-28 | 2020-03-17 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 325 (500319), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
RU2717022C1 (ru) * | 2019-06-28 | 2020-03-17 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 328 (500322), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
RU2717451C1 (ru) * | 2019-06-28 | 2020-03-23 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 323 (500317), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
RU2717435C1 (ru) * | 2019-06-28 | 2020-03-23 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 326 (500320), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
RU2717420C1 (ru) * | 2019-06-28 | 2020-03-23 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 327 (500321), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
RU2707505C1 (ru) * | 2019-09-17 | 2019-11-27 | федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО "ПИМУ" Минздрава России) | Способ лечения бактериальных инфекций дыхательных путей |
US20210187046A1 (en) | 2019-12-19 | 2021-06-24 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof |
CN113214364B (zh) * | 2020-01-21 | 2022-11-22 | 天津大学 | 一种多重耐药鲍曼不动杆菌识别元件的挖掘与验证 |
FR3110574A1 (fr) * | 2020-05-20 | 2021-11-26 | Vetophage | Capture de bacteries a l’aide de bacteriophages ou de proteines de bacteriophage |
EP4074831A4 (en) | 2020-05-22 | 2023-08-09 | Lysentech Co., Ltd. | NEW POLYPEPTIDE, FUSION POLYPEPTIDE AND ANTIBIOTIC AGAINST GRAM-NEGATIVE BACTERIA INCLUDING THEM |
EP4199961A4 (en) * | 2020-08-20 | 2024-03-13 | The Board of Regents of the University of Texas System | COMBINATION IMMUNOTHERAPY METHODS FOR THE TREATMENT OF CANCER |
CA3218291A1 (en) * | 2021-05-12 | 2022-11-17 | Lior Moshe ZELCBUCH | Staphylococcus bacteriophage and uses thereof |
WO2023101639A1 (en) * | 2021-11-30 | 2023-06-08 | Yildiz Teknik Universitesi | Antimicrobial agent for lysis of s. aureus |
CN114807106B (zh) * | 2022-04-25 | 2023-09-01 | 昆明市延安医院 | 一种裂解酶pEf51和穿孔素蛋白pEf191的应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
ES2145019T3 (es) * | 1992-06-25 | 2000-07-01 | Aventis Res & Tech Gmbh & Co | Pseudomonas aeruginosa y su utilizacion para la preparacion de l-ramnosa. |
CA2186962A1 (en) | 1994-04-05 | 1995-10-12 | Richard M. Carlton | Antibacterial therapy with genotypically modified bacteriophage |
RU2112800C1 (ru) * | 1996-03-29 | 1998-06-10 | Государственный научный центр прикладной микробиологии | Штамм пилеспецифического бактериофага pseudomonas aeruginosa гнцпм n 03, используемый для приготовления лечебного препарата против синегнойной палочки |
WO1997039111A1 (en) | 1996-04-15 | 1997-10-23 | Nymox Corporation | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
US7138419B2 (en) * | 2000-12-27 | 2006-11-21 | Corus Pharma, Inc. | Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate |
DE10115310A1 (de) | 2001-03-28 | 2002-10-10 | Nodar A Daniela | Bakteriophagen-Präparation |
ATE370228T1 (de) * | 2002-03-25 | 2007-09-15 | Univ Warwick | Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen |
GB0300597D0 (en) * | 2003-01-10 | 2003-02-12 | Microbiological Res Authority | Phage biofilms |
US20050095222A1 (en) | 2003-10-29 | 2005-05-05 | Taro Suzuki | Allergen inhibitor, allergen-inhibiting method, allergen-inhibiting fiber and allergen-inhibiting sheet |
CA2586611A1 (en) | 2004-11-02 | 2006-05-11 | Gangagen Life Sciences Inc. | Encapsulated bacteriophage formulation |
AU2005301048A1 (en) | 2004-11-02 | 2006-05-11 | Chr. Hansen A/S | Bacteriophage compositions |
WO2006063176A2 (en) | 2004-12-06 | 2006-06-15 | The Government Of The Usa As Representedtd By The Secretary Of The Dept Of Health And Human Services | Inhibition of biofilm formation using bacteriophage |
US20080260697A1 (en) | 2005-05-26 | 2008-10-23 | Gangagen Life Sciences Inc. | Bacterial Management in Animal Holding Systems |
CN101437532B (zh) * | 2006-05-05 | 2013-08-21 | 冈戈根股份有限公司 | 噬菌体衍生的抗微生物活性剂 |
IE20060488A1 (en) * | 2006-06-29 | 2008-01-09 | Teagasc Agric Food Dev Authori | Recombinant staphylococcal phage lysin as an antibacterial agent |
CN101003793A (zh) * | 2007-01-11 | 2007-07-25 | 中国人民解放军第三军医大学 | 噬菌体对环境中致病菌的净化技术 |
US20110143997A1 (en) | 2007-03-30 | 2011-06-16 | Dow Agrosciences Llc | Phage receptor binding proteins for antibacterial therapy and other novel uses |
EP2103308A1 (de) * | 2008-03-20 | 2009-09-23 | PhytoLine GmbH | Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen |
CA2638130A1 (en) * | 2008-07-21 | 2010-01-21 | Canadian Forest Products Ltd. | Composite wood product and method of manufacture utilizing wood infected by bark beetles |
CA2736062A1 (en) * | 2008-07-24 | 2010-01-28 | The United State Of America, As Represented By The Secretary Of Agricuure | Triple acting antimicrobials that are refractory to resistance development |
GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
AU2009302985B2 (en) * | 2008-10-10 | 2015-09-10 | Lusomedicamenta, S.A. | Antibacterial phage peptides and methods of use thereof |
KR101016918B1 (ko) | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질 |
CA2751641C (en) | 2009-02-06 | 2018-11-13 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Antibacterial phage, phage peptides and methods of use thereof |
CN102482655B (zh) | 2009-06-26 | 2018-04-10 | 莱桑多公司 | 抗微生物剂 |
EP3789031B1 (en) * | 2010-09-17 | 2023-08-02 | Technophage, Investigação e Desenvolvimento em Biotecnologia, SA | Antibacterial phage, phage peptides and methods of use thereof |
CA2833176C (en) * | 2011-04-12 | 2023-05-16 | C.B. Appaiah | Chimeric antibacterial polypeptides |
-
2011
- 2011-09-19 EP EP20194660.5A patent/EP3789031B1/en active Active
- 2011-09-19 US US13/823,519 patent/US9222077B2/en active Active
- 2011-09-19 EP EP18192766.6A patent/EP3443970B1/en active Active
- 2011-09-19 CA CA3154006A patent/CA3154006A1/en active Pending
- 2011-09-19 RU RU2017106290A patent/RU2725726C2/ru active
- 2011-09-19 CA CA3048783A patent/CA3048783C/en active Active
- 2011-09-19 SG SG2013019385A patent/SG188566A1/en unknown
- 2011-09-19 RU RU2013117275A patent/RU2614114C2/ru active
- 2011-09-19 ES ES18192766T patent/ES2825050T3/es active Active
- 2011-09-19 ES ES11820825T patent/ES2703629T3/es active Active
- 2011-09-19 BR BR112013006400-5A patent/BR112013006400B1/pt active IP Right Grant
- 2011-09-19 JP JP2013529096A patent/JP6058540B2/ja active Active
- 2011-09-19 EP EP11820825.5A patent/EP2616087B1/en active Active
- 2011-09-19 EP EP23178561.9A patent/EP4332217A3/en active Pending
- 2011-09-19 ES ES20194660T patent/ES2956367T3/es active Active
- 2011-09-19 CA CA2811472A patent/CA2811472C/en active Active
- 2011-09-19 WO PCT/PT2011/000031 patent/WO2012036580A2/en active Application Filing
- 2011-09-19 AU AU2011302722A patent/AU2011302722B2/en active Active
- 2011-09-19 CN CN201180054190.XA patent/CN103732235B/zh active Active
- 2011-09-19 PT PT11820825T patent/PT2616087T/pt unknown
- 2011-09-19 PT PT181927666T patent/PT3443970T/pt unknown
- 2011-09-19 PL PL20194660.5T patent/PL3789031T3/pl unknown
-
2015
- 2015-11-13 AU AU2015255313A patent/AU2015255313C1/en active Active
- 2015-11-17 US US14/943,082 patent/US9399049B2/en active Active
- 2015-12-14 JP JP2015243657A patent/JP6234983B2/ja active Active
-
2016
- 2016-07-22 US US15/216,875 patent/US9737579B2/en active Active
- 2016-08-25 AU AU2016219667A patent/AU2016219667B2/en active Active
- 2016-09-16 JP JP2016181177A patent/JP6355691B2/ja active Active
Also Published As
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT) |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/09/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |